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COMBINATION TOPICAL THERAPY FOR VULVAR LICHEN SCLEROSUS 
IN ADULT WOMEN 
DANIELLE MURRAY 
ABSTRACT 
Introduction:  
Vulvar lichen sclerosus (LS) is characterized by thinning of the epithelium, and 
whitening of the vulvar skin which can lead to the characteristic symptoms of burning 
and itching. There is no cure for vulvar LS and topical corticosteroids are first-line 
treatment. The aims of this thesis are to propose a study to determine whether topical 
combination therapy with an ultra-potent corticosteroid and calcineurin inhibitor leads to 
greater improvement in symptoms and clinical appearance of disease than traditional 
first-line treatment with an ultra-potent corticosteroid alone, and to evaluate relapse rates 
between the combination therapy group compared to the topical corticosteroid only 
group.  
Review of literature:  
The ultra-potent corticosteroid clobetasol propionate is currently the first-line treatment 
for women with LS however not all patients achieve remission, and many patients have 
relapses. Topical calcineurin inhibitors such as tacrolimus are considered to be second-
line treatments for vulvar LS and may eliminate the side effects of thinning that can occur 
with long-term therapy with corticosteroids.  
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Methods:  
A single-center randomized control trial will be conducted with post-menopausal women 
recruited from the dermatology and gynecology at Boston Medical Center. The patients 
will be randomized to either three months treatment with daily clobetasol propionate in 
the morning and tacrolimus ointment in the evening, or clobestasol propionate in the 
morning with a vehicle ointment in the evening. The patients will be evaluated for 
improvement in symptoms of burning and itching, and for clinical appearance of 
erythema, whitening of the skin, and hyperkeratosis, purpuric lesions and excoriations. 
The patients will also be followed for a year post-treatment for signs of relapse.   
Conclusion:  
The incidence of vulvar LS is increasing and may be under-reported. Though 
corticosteroids are an effective treatment for most patients, combination therapy with 
topical tacrolimus may increase the proportion of patients who achieve remission for 
vulvar LS and will improve their quality of life. 
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INTRODUCTION 
Background 
Lichen sclerosus (LS) is a dermatologic condition which involves thinning, whitening, 
inflammation and scarring of the skin.  LS can affect either gender and be located on any 
area of the skin. LS is commonly found in the anogential region. When it occurs in a non-
genital site, it is known as extra-genital LS. Females are more likely to be affected with 
anogenital or vulvar lichen sclerosus. There is a bimodal distribution of the disease in 
females with one peak in young girls, and another peak in post-menopausal women. The 
pathogenesis of LS is not entirely understood but it is known that women with LS have a 
higher rate of autoimmune disease. Other associations such as trauma, infections, familial 
disease and hormonal influences have been investigated. Women with vulvar LS can be 
asymptomatic, but commonly complain of itching, burning, and dyspareunia which 
effects their quality of life. Upon examination of the vulva, clinicians are able to see 
white patches, areas of erythema, excoriations and thinning of the skin which in severe 
cases can lead to permanent disfigurement and fissuring. Another potential complication 
of vulvar LS is the risk of malignant transformation to squamous cell carcinoma.    
 There are many treatments for vulvar LS including: ultra-potent topical 
corticosteroids, potent topical corticosteroids, topical calcineurin inhibitors, topical 
hormonal therapies, retinoids, topical vitamin E, light and laser treatments, and surgery. 
There is no definitive cure for LS and many patients experience relapses of their disease. 
Currently, topical ultra-potent or potent corticosteroids are recommended as first line 
treatment of vulvar LS3.  
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Statement of the Problem 
Despite the fact that there is no definitive cure for vulvar LS, topical ultra-potent 
corticosteroids and topical calcineurin inhibitors have been proven to reduce the 
symptoms and clinical appearance of vulvar LS. Though these treatments have been 
studied and found to be effective individually, neither of these treatments is curative and 
reoccurrence of signs and symptoms is common. Additionally, there are some women 
who are unresponsive to multiple types of treatments. Though many treatment options 
have been studied and compared, no studies have yet evaluated effectiveness in 
combination. 
 
Hypothesis 
Topical corticosteroids and calcineurin inhibitors in combination will produce a higher 
rate of improvement in signs and symptoms of vulvar LS at three months, and remission 
at one year than either topical treatment alone.  
 
Objectives and specific aims 
Topical calcineurin inhibitors and topical ultra-potent corticosteroids have different 
mechanisms of action and are both effective in treating vulvar LS. When used in 
combination the resulting treatment may be more effective. If this hypothesis is true, 
future guidelines may recommend combination therapy instead of monotherapy in the 
treatment of vulvar LS due to decreased rates of relapse and greater improvement in 
symptoms and clinical presentation. Specifically, the proposed study will:  
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1. Determine whether topical combination therapy with an ultra-potent 
corticosteroid and calcineurin inhibitor leads to greater improvement in symptoms 
and clinical appearance of disease than first-line treatment of ultra-potent 
corticosteroid 
2. Evaluate remission rates at one year between combination therapy group 
compared to topical corticosteroid group alone 
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REVIEW OF THE LITERATURE 
Overview 
 
Definition 
Lichen sclerosus (LS) is a chronic dermatological condition which is characterized by 
inflammation, thinning of the epithelium, changes and whitening of the skin, and can be 
found throughout the body but is most commonly located in the anogenital region4. LS 
was originally described by French dermatologists in the late 1800s, and was named 
lichen sclerosis et atrophicus. Some simply refer to it as LS due to the lack of histological 
atrophy in some cases5. The male form of LS was defined in 1928 and was originally 
called balantitis xerotica obliterans before it was understood to be a manifestation of  
LS5.   
Figure 1. 65 year-old woman with coalescing white papules and plaques, and 
distortion of vulvar architecture typical of vulvar LS1. 
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Epidemiology 
  
The epidemiology of LS has not been thoroughly studied, and most data on incidence and 
distribution comes from clinical observations. In a landmark study from 1971, Wallace 
found the incidence of LS was found to be 0.1-0.3% of patients referred to dermatology6 
1 . In a historical cohort study in the Netherlands, the incidence rate of vulvar LS 
increased from 7.4 to 14.6 in 100,000 women-years from 1991 to 20117. The incidence of 
LS is thought to be higher than what has been reported due to the fact that patients with 
LS are treated by different specialists including primary care doctors, urologists, 
gynecologists and dermatologists8. Additionally, patients may avoid seeking medical care 
due to cultural barriers, misunderstanding or embarrassment of genital-area disease.  
Another factor that may affect the incidence of LS is that the disease can present 
without symptoms, and patients may not notice any changes in appearance of their skin 
due to difficulty visualizing the affected area. Additionally, women who are 
asymptomatic may defer the genital skin exam at skin check appointments with 
dermatologists. Though asymptomatic LS may reduce the reported incidence, in a study 
of 225 women with vulvar LS, only 4 women (2%) were asymptomatic at the time of 
disease diagnosis9.  
The ratio of females to males is thought to be 10:1 but varies between 
reviews5.Extragenital disease accounts for 15-20% of cases however a recent 
retrospective study in Lebanon found the incidence of extragenital LS to be 68.33% of 
LS cases10. There may be variability between populations that has not been fully 
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elucidated. Vulvar LS has a bimodal distribution and is found in women in their 50s or 
60s with 7-15% of cases being found in pre-pubertal girls5. For male genital LS, a similar 
bimodal distribution is found with presentation in adults between 30-50 years old5. LS 
has been found in a variety of races, but it is most commonly found among Caucasians11.  
 
Pathogenesis/ risk factors  
 
LS is non-transmittable from one patient to another, and the etiology of the disease is still 
misunderstood. Some researchers believe that LS may be associated with vector-borne 
pathogens. Acrodermatitis chronica atrophicans which is caused by Borrelia burgdorferi 
shares histological similarities with LS, and several studies have found evidence of B. 
burgdorferi associated with LS12. A study by Eisendle et al. in Austria found B. 
burgdorferi by using focus-floating microscopy in 63% of LS samples with a 
significantly increased chance of finding B. burgdorferi in early disease12.  However, a 
conflicting study using PCR to detect B. burgdorferi in North American patients found no 
evidence of infection in all 10 samples13.  Further research is necessary to determine 
whether the association with B. burgdorferi is causal.  
Viral causes have also been investigated as a trigger or source of LS but the 
available data is conflicting. Zhang et al. found in Chinese boys that Epstein Barr Virus 
(EBV) was associated with 38.3% of LS cases, whereas EBV was found in 13.3% of 
healthy men. Additionally, none of the boys with LS were found to be infected with 
human papillomavirus (HPV)14.  A study by Nasca et al. conducted on adult men found 
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that 17.4% of LS patients had detectable HPV, whereas only 8.7% of controls were found 
to have HPV15. A study of vulvar LS found EBV DNA in 26.5 of vulvar biopsies with 
0% of the control biopsies having EBV DNA16. 
Along with viral and bacterial infections, the association between autoimmune 
disorders and LS has been investigated. A study by Kreuter et al. investigated the 
prevalence of autoimmune disorders associated with LS in male and female populations. 
The women were more likely to have one or more autoimmune disorders with an odd’s 
ratio of 4.3 compared to men, and they were most commonly found to have autoimmune 
thyroid disease17.  An epidemiological study in 729 men and women with genital LS also 
found a high rate of thyroid disease. Thyroid disease was significantly more common in 
women compared to men at a rate of 19.4% and 10.7% respectively18.  Additionally, a 
case control study of 190 post-menopausal women with LS found 28% of participants to 
have an autoimmune disease with thyroid disease being most common at 16.3% of the 
women. Vitiligo, alopecia areata, celiac disease, rheumatoid arthritis, type one diabetes 
mellitus, pernicious anemia, morphea, and primary biliary cirrhosis were also found in 
the population19.  
Similar to autoimmune disorders, there may be a familial pattern in the 
distribution of LS. In an observational cohort study of 1052 patients with LS, 12% had a 
family history of LS and the patients with familial LS had a 2% higher proportion of 
associated autoimmune disease20. Human leukocyte antigen markers along with 
autoimmune markers have also been associated with intra-familial LS which could play a 
role in pathogenesis21.  
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LS has also been found to have an association with trauma or irritation in isolated 
cases.  There are reports of LS being associated with areas of skin that were prior burn 
sites, surgical wounds, vaccination sites, or sites of sunburn22.  In a retrospective study of 
male genital LS by Edmonds et al., two men were found to have LS at the site of a 
previous injury and two men developed LS in areas with genital jewelry23. Additionally, 
chronic urine exposure is thought to have been a cause of LS as was seen is a study of 12 
patients with periostomal LS who reported urine leakage around the site of their 
urostomy24. The anatomical distribution of genital LS favors areas exposed to urine, 
especially in men where it is most commonly found in the visceral prepuce, distal penis, 
frenulum, and perimeatal glands while it rarely involves the anus23.  Genital LS is rarely 
found in circumcised men. 
The role of hormones in the pathogenesis of LS is controversial. In a study by 
Friedrich et al., the levels of serum androgens and estrogen levels of women with genital 
LS were compared to a control group of women without genital LS. This study found that 
women with genital LS were found to have significantly lower serum dihydrotestosterone 
and andro-stenedione with elevated free testosterone compared to the control group 
women, whereas the estrogen levels were not significantly different between groups25. 
Another retrospective case-control study of pre-menopausal women with genital LS who 
were taking oral contraceptive pills found that women with LS were more likely to be 
taking pills with anti-androgen activity (70%) compared to the control group without LS, 
in which 48.7% were using oral contraceptives with anti-androgen properties26. 
Additionally, a study examining the histological changes from LS found a dramatic 
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decrease in the density of androgen receptors in skin affected by genital LS, whereas 
there was a less dramatic decrease with extra-genital LS. The degree of reduction in 
density of receptors correlated with the severity of disease27. These findings indicate that 
in some cases of genital LS, the lack of 5-alpha reductase activity or androgen receptors 
may influence the development of genital LS 25 27.  
 
Clinical presentation  
 
Women with vulvar LS often report vaginal itching, burning, dyspareunia, dysuria, and 
painful defecation with severe cases resulting in painful fissuring28. The severe scarring 
caused by vulvar LS can lead to permanent deformities that are sometimes treated with 
surgeries. Pre-pubertal girls often report similar symptoms which can be mistaken by 
health-care practitioners or family members for sequelae of sexual abuse29. Vulvar LS 
rarely involves the vaginal mucosa, but isolated biopsy-proven cases involving the 
vaginal wall have been reported30. 
Along with the classic symptoms of vulvar LS such as vulvar itching, burning, 
and dyspareunia, many women suffer from comorbid conditions.  In a retrospective 
review on 308 women presenting to the Michigan Center for Vulvar disease, women 
filled out questionnaires self-reporting comorbidities.  They found that women with LS 
had an increased rate of thyroid disorders, urge and stress incontinence, inflammatory 
bowel diseases, chronic constipation, and irritable bowel disease, vulvar pain, interstitial 
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cystitis, and fibromyalgia. The only condition with a lower than average incidence in this 
population was overactive bladder31.  
Many women suffer from a lower quality of life due to genital LS. This was 
assessed in a study of Dutch women with genital LS who were given surveys regarding 
their health-related quality of life including the Skindex-29 which is specific to skin 
conditions, SF-12 which is specific to chronic diseases, and EQ-5D which measures self-
rated health32. The Skindex-29 score showed that most of these women to have a 
moderately impaired health-related quality of life. It showed an increase in symptoms 
with increased severity of disease, and also found heavy smokers to have an increased 
symptom score32. The EQ-5D and SF-12 surveys also showed women with LS to have 
lower scores, which indicates a lower health-related quality of life, than the general 
Dutch public32.  
 A similar study was done to evaluate quality of life and sexual functioning by 
using surveys of Dutch women with LS compared to an unaffected control group. The 
Dermatology Life Quality Index found LS had a large impact on their quality of life. It 
effected sexual functioning while interfering less work or school33. The Female Sexual 
Functioning Index showed that the LS patients surveyed had significantly lower scores 
for arousal, lubrication, orgasm, satisfaction, pain, and desire compared to the control 
group33. The Female Sexual Distress Scale also showed that women with LS had an 
average score of 26.08 compared to 9.97 for controls with scores greater than 15 
significant for sexual distress33.  
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Diagnosis  
 
LS can be diagnosed clinically by signs and symptoms or be biopsy-proven. The 
“Evidence-based (S3) Guideline on (anogenital) Lichen Sclerosus” published in 2015 in 
The European Journal of Dermatology and Venereology states that not every patient 
needs to be biopsied, but they should have biopsies with histological examination if the 
clinical diagnosis is uncertain, if the first-line treatment fails, if the lesion may be 
malignant, and if the patient is therapeutically circumcised3. Histological examination of 
biopsied lesions of LS show epithelial thinning, hyperkeratosis, plugging of the follicles, 
and vacuolar degeneration of the basal layer8. Additionally, LS is associated with 
homogenization of dermal collagen and a lymphocytic infiltrate, classically band-like 
within the dermis. 
Figure 2. Histology of vulvar LS depicting thinning of the epidermis, 
hyperkeratosis, follicular plugging, homogenization of dermal collagen and band-
like lymphocytic infiltrate within the dermis2 
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 Dermoscopy has also become a useful tool in evaluating the lesions of LS which 
can help strengthen a clinician’s suspected diagnosis of LS. In a retrospective study of 
dermoscopy images of patients with and without genital LS, all cases of genital LS 
showed patchy yellow-white areas associated with linear telangectasias (85.7%) or dotted 
vessel (71.4%) with only 7.1% showing keratotic plugs, scales, chrysalis structures2. This 
differed from the extra-genital LS group which had a greater proportion of scales, 
keratotic plugs, and chrysalis structures while only having visible linear vessels in 33% of 
patients and dotted vessels in 13.3% of patients2.  
 
Treatment options 
 
Though there is not a single treatment that is successful in every patient with LS, there 
are a wide variety of treatment options utilized by healthcare practitioners. The most 
commonly recommended topical options include ultra-potent topical corticosteroids, 
potent topical corticosteroids, and topical calcineurin inhibitors which will be discussed 
further below. 
Due to fears of long-term use of topical corticosteroids including thinning of the 
epithelium, other options for treatment have been investigated. A study was done 
evaluating the combination of a cream containing avocado and soybean extracts with 
anti-oxidative and lenitive agents in combination with dietary supplements with avocado 
and soybean extracts with vitamin E and para-aminobenzoic acid. This study found 
improvement in 70% of patients in their subjective scores of burning, itching and 
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dyspareunia and 72.2% of objective scores evaluating erythema, leukoderma, 
sclerosis/atrophy, hyperkeratosis, and itching related excoriations while three patients 
dropped out of the study and switched to topical corticosteroids34.   
 Topical hormonal creams such as testosterone propionate and dihydrotestosterone 
have been used for treatment since there is thought to be a hormonal link to genital lichen 
sclerosus. Studies have shown that testosterone can be an effective treatment but it has a 
higher rate of recurrence and than patients treated with the first-line clobetasol 
propionate35. Side effects such as hirsutism and clitoromegaly limit the usage. The true 
efficacy of topical testosterone is controversial. Some believe that the positive effects 
seen in studies of topical testosterone treatment were related to a component of the 
vehicle rather than testosterone itself. Progesterone was another hormonal agent 
previously used for vulvar LS but has been shown to be less effective than the first-line 
treatments36.  
 Along with topical treatments, light and laser therapies have been utilized in the 
treatment of vulvar LS. In a randomized control study, four treatments of 5-
aminolevulinic acid photodynamic therapy were found to be more effective in reducing 
disease severity and relapse compared to eight weeks of 0.05% clobetasol propionate; 
however the cost and pain associated with treatment may be limiting37. Ultraviolent A1 
therapy has all been shown to help patients with severe vulvar LS but may be more 
effective for extra-genital LS38.  
Topical and systemic retinoids may also be alternatives for patients with vulvar 
LS. A recent study found that in 17 patients with vulvar LS, 12 patients had a response to 
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treatment with topical tretinoin39. Larger controlled trials are needed to evaluate the 
efficacy of retinoids in treatment of vulvar LS.  
When medical treatments are ineffective in treating genital lichen sclerosus, 
surgical management may be an alternative option. Also, surgical treatment may be 
indicated when patients with vulvar LS develop SCC. Clinicians utilize vulvectomies, 
cryosurgery, and carbon dioxide laser therapy but these treatments are reserved cases that 
are unresponsive to medical therapy40. 
 
Complications of vulvar ls 
 
Vulvar LS can cause significant pain and discomfort, and also has a risk of malignant 
transformation to squamous cell carcinoma. In a Dutch historical cohort study of women 
with vulvar LS between 1991 and 2011, they found the incidence of transformation to 
SCC to be 6.7% (95% CI, 3.2%-5.1%) with 20 years of follow up7. The 10 year incidence 
rate was increased in the age group of 70 and older at 5.9% compared to 3% for 50-70, 
and 1.8% below 507.  Many studies have proven an association between vulvar LS and 
vulvar SCC but more studies are necessary to show whether there are certain risk factors 
in patients with vulvar LS that make malignant transformation more likely. A recent 
study showed patients with treated LS have less likelihood of having malignant 
transformation41. 
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Existing research 
Though vulvar LS has been more extensively studied than male genital LS and extra-
genital LS, there is not a standardized treatment regimen recommended for every 
woman3. Also, the current treatment regimens aim to eliminate signs and symptoms such 
as pruritus, erythema, pallor and fissures but treatment is not curative and many 
previously treated women have relapsing episodes of genital LS3. In a survey of 
physicians conducted by the International Society for the Study of Vulvovaginal Disease, 
clobetasol propionate was used by the majority of the physicians as the first-line 
treatment (85%) while tacrolimus, other topical steroids, and intra-lesional steroids were 
used as second line treatment42. Additionally, the dermatologists surveyed were more 
likely to treat asymptomatic LS including maintenance therapy whereas gynecologists 
tended to treat symptomatic presentations42. The European Academy of Dermatology and 
Venereology released guidelines in 2015 that stated that potent and very potent steroids 
are the treatment of choice for vulvar LS, but that various options should be discussed 
with patients3. 
 
Topical corticosteroids  
 
The use of clobetasol propionate for treatment of vulvar LS has been validated by many 
studies including a randomized study by Bracco et al., in 1993 with 79 patients ranging 
from age 27-83. Bracco compared clobetasol propionate 0.05% applied twice daily to 
testosterone cream 2%, progesterone 2%, and a non-medicated cream-based preparation 
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for three months. Each patient had vulvar LS proven by punch biopsies prior to the study 
and features of LS were graded 1-3 with three being the most severe. The patients’ 
symptoms of burning, pain, and dyspareunia was classified with a scoring system 
between 0-3, and objective appearance was also scored from 0-3 based on hyperkeratosis, 
thickness of plaques, atrophy and erosions. The patients were considered to have 
persistence of the disease if the scores remained the same, improved if the scores lowered 
after the trial, and if they no longer had symptoms of symptoms or lesions they were 
considered to be in remission. The clobetasol group was found to have the highest rate of 
remission at 75% compared to 10.5% of the control cream group, 20% of the testosterone 
group, and 10% of the progesterone group. Additionally, the group receiving clobetasol 
was the only group to show histologic improvement with a p value of <0.001 with a CI of 
2.29-4.6536. Though this study showed that clobetasol was effective in treating vulvar LS, 
there were only 19-20 women in each treatment group. Additionally, there was a wide 
range of ages included in this study and it is possible that younger women may have 
fewer comorbidities and might respond to treatment more quickly. Though the study 
found clobetasol propionate to be the most effective in treating LS, long-term side effects 
such as rebound reactions, infections, reactivations of viruses, and systematic absorption 
were not evaluated. The study also did not follow women long term for recurrence of 
disease. 
Due to the fear of the adverse reactions from an ultra-potent corticosteroid such as 
clobetasol propionate, potent corticosteroids have also been studied as alternative 
treatments. Virgil et al. compared 12- week treatment with clobetasol propioate 0.05% 
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and mometasone furoate 0.1% in a tapering method in a randomized single center 
study43. The patients reported their symptoms of burning and itching in an interview and 
were scored using a visual analog scale (VAS) with 10 being the highest intensity in each 
category. The scores were added together which was considered the Global Subjective 
Scale (GSS) with the highest possible score of 20. Two practitioners who were not 
blinded to the treatment arms evaluated the patients clinically using a global assessment 
score (GOS) initially with erythema, leukoderma, sclerosis scarring, hyperkeratosis and 
purpuric lesions and excoriations (graded from 0=absence to 3=severe) however sclerosis 
scarring was not included in further clinical evaluations because of it’s irreversible 
nature43. The GOS score of 12 was considered the highest possible score with a score 
with a score less than or equal to four being a responder to treatment. The study also 
evaluated the GOS75 GSS75, and GOS50 GSS50 which indicated improvement in scores 
in 75% and 50%. Twenty-seven women were randomized into each group and were 
matched for disease severity and demographics, however two women in the clobetasol 
propionate group and one women in the mometasone furoate group were lost to follow 
up.  
In both the clobetasol propionate and mometasone furoate groups the patients had 
a significant response to treatment in 88.9% of the clobetasol group and 89% of the 
mometasone group and the difference in response was not found to be significant with 
Fischer’s test. The clobetasol group had 59% of patients reach GSS75 and 37% reach 
GOS75 whereas the mometasone group had a 67% reach GSS75 and 48% GOS75. 
However the difference was not significantly different with a p-value of 1. Though this 
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study showed that both treatment groups were effective, it was not a double-blind trial 
and it is possible that the clinicians had bias when evaluating the patients. Additionally, 
this study did not evaluate histological improvement or relapse rates, which could have 
been different between groups.  
A larger prospective cohort, open-label non-comparative study was conducted by 
Virgili et al. to evaluate the efficacy of the potent corticosteroid mometasone furoate 
0.1% administered for 12 weeks.  The patients’ symptoms of itching, burning, 
dyspareunia using a VAS from 0-10 for each symptom with a total possible GSS of 30. 
The patients were considered responders if their subjective scores were less than or equal 
to 5/30. The clinical signs of erythema, leukoderma, hyperkeratosis and purpuric lesions 
and were given a score between 1-5 which was called the Investigator Global Assessment 
(IGA). A score of less than or equal to 2 indicated that the patient was “treatment 
responsive”.  During the first month, patients administered the topical medication daily, 
then reducing the dosage to every other day for the second month, and twice weekly for 
the third month. The primary endpoint of clinical resolution was achieved by 80.7% of 
the 147 patients, while 19.3% were non-responders44. Additionally, the secondary 
endpoint of symptom improvement was evaluated and there was a significant decrease in 
itching (p= 0.001), burning (p=.0000001) and dyspareunia (p=.0000001) in both the 
responder and so-called non-responder groups. None of the patients noted an adverse 
reaction44. While this study showed that momematsone furoate is effective in treating 
vulvar LS in a large study compared to many current studies on vulvar LS, it was limited 
in that there was not a control group available for comparison.  
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 A study has also been done to compare different methods of mometasone furoate 
administration. Patients were randomized to either continuous or tapered treatment and 
symptoms were evaluated using the VAS for burning and pruritus which has been 
utilized in previous studies. Dysparunia was not included as a symptom in the study 
because not all patients were sexually active. The clinical parameters of erythema, 
leukoderma, hyperkeratosis and purpuric lesions and excoriations were evaluated using 
the GOS.  In the continuous group, patients applied topical mometasone furoate for 
twelve weeks, five days per week. In the tapered group, they applied it four weeks five 
days per week followed by four weeks of every other day use, then twice weekly 
application for another four weeks. The same parameters of leukoderma, hyperkeratosis, 
erythema, and purpuric lesions/excoriations were evaluated for each patient before and 
after treatment. The percentage of patients that achieved a clinical resolution of vulvar LS 
was 84% of the daily treatment group, and 78% of the tapered group, but there was no 
significant difference by Fischer’s exact test and the relative risk of non-response in the 
tapered to continuous group was 0.94 (95% CI 0.26-3.40)45.  Though this study showed 
improvement in both groups, the patients were not blinded to their treatment and there 
was not a control group comparison. Additionally, the authors of the study acknowledged 
that there is not a single validated tool available used to assess vulvar LS severity.  
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Topical calcineurin inhibitors   
 
In addition to ultrapotent and potent corticosteroids, topical calcineurin inhibitors are 
used for treatment of vulvar LS. Since calcineurin inhibitors have a different mechanism 
of action by reducing T-cell differentiation, it is thought that their use may eliminate 
some of the negative side effects of topical corticosteroids including skin atrophy, striae 
formation, systemic absorption, hypo-thalamic-pituitary axis suppression and fungal 
infections46. The first documented use of tacrolimus for treatment of vulvar LS was 
reported by Assmann et al, for use in a 71-year-old woman who was not able to achieve 
long-term remission with intermittent use of mometasone furoate and clobetasol 
propionate47. The patient applied tacrolimus 0.1% twice daily and had improvement in 
the appearance, itching, and pain with concomitant histological improvement47.  
 Virgili et al. did a small study on the therapeutic effects of tacrolimus 0.1% on 
women with vulvar LS who were unresponsive or poorly responsive to at least one three 
month cycle of corticosteroid, and either an additional cycle of corticosteroids or another 
treatment. Eleven women were eligible for the study and were instructed to apply 
tacrolimus on the vulva twice daily for 6 weeks, then tapering to once daily for 15 days 
and twice weekly for the final four weeks. The patients were evaluated using a VAS scale 
for itching, burning, and dyspareunia, and there were evaluated by the same clinician for 
the thirteen parameters. The initial scores were compared to final scores with >55% 
reduction being good improvement. The study showed that 4 women had complete 
remission, 4 more women had good improvement, and two women had a slight 
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improvement in symptoms, while objective clinical resolution was seen in one patient, 
good improvement in another patient, 6 patients had slight improvement, one with no 
change and one patient with worsening clinical appearance48.  Three patients were also 
found to have brown pigmentation on the labia majora. Though this showed that women 
who had severe vulvar LS unresponsive to first-line treatment may respond to tacrolimus, 
it was a small sample size with only 11 women. The group also represents women with 
severe disease, and they were not compared to another treatment or control arm. Though 
the majority of women had improvement in their subjective and objective features, 
Additionally, the patients were followed for 2-7 months after the treatment, and the long-
term relapse rates are unknown.  
 In a prospective randomized trial of females with genital LS by Funaro et al. 58 
patients were randomized to either three months of clobetasol propionate 0.05% ointment 
or three months of tacrolimus 0.1% ointment. The patients used the VAS-PR and VAS-
BP scales to evaluate itching and burning, and they were also instructed to report any side 
effects. Additionally, a dermatologist examined the patients’ vulvas for white patches, 
atrophy, erythematous patches, erosions and ulcerated lesions, and lichenification on a 
scale from 0-3 (three being most severe). In both the clobetasol propionate group and the 
tacrolimus group, the patients improved clinically however the clobetasol propionate 
group had a significantly higher absence of signs and symptoms with 15 patients without 
symptoms compared to 4 (chi-square= 10.35, p=.002)49.  VAS-PR and VAS-BP were not 
found to be significantly different with P values of 0.108 and 0.172 respectively. There 
was no significant difference in the amount of one or more side-effects between groups, 
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however the tacrolimus group reported significantly more burning (22 vs. 13 p=0.014)49. 
Though there was no significant difference between the two groups, there were 5 patients 
under the age of 18 and 4 of them were randomized to the clobetasol propionate group 
which may have accounted for the increased response to treatment. Additionally, many of 
the patients had been previously treated for their vulvar LS with a wide variety of 
therapies and though the groups did not differ significantly in participants with previous 
treatment, the study did not specify if the types of previous treatments in the groups were 
comparable. Though this study evaluated objective signs of disease improvement, and the 
patient’s subjective symptoms, histologic improvement was not evaluated.  
Goldstein et al. compared lower potency calcineurin inhibitors to ultra-potent 
corticosteroids in a double-blind trial comparing the topical pimecrolimus 1% cream 
(applied twice daily) and clobetasol propionate 0.05% cream for a 12-week treatment 
period46. Response to treatments were measured by subjective symptoms of pruritus and 
burning/pain with the VAS-PR score and the VAS-BP score respectively, pathologist 
evaluation of inflammation on biopsy, and clinical evaluation of a scale of 0-3 for disease 
severity, lichenification, and fissuring. There was a small sample size with 17 in the 
pimecrolimus group and 19 in the clobetasol group. Dermatopathologists found both 
groups to have significant improvement in inflammation however clobetasol was superior 
in improving inflammation (P=.015)46. Also, 8 women in the pimecrolimus group were 
non-responders when histology was examined compared to 1 woman in the clobetasol 
group.  Both groups had improvements in patients’ objective signs and symptoms of 
itching (p=.319 for VAS-PR) and burning (p=.932 for VAS-BP) and they were not found 
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to be statistically different46. Though there was significantly greater histological 
improvement in the clobetasol propionate group, the clinical importance of this finding 
was unclear because both groups had significant improvement in signs and symptoms of 
vulvar LS. This study also did not include long-term follow up and rates of relapse 
between the groups was not evaluated.    
 Though many therapies have been effective in the treatment of genital LS, the 
most effective treatments only have remission rates of about 80%. The symptoms of LS 
including pruritus, dyspareunia, and burning can be debilitating and greatly reduce the 
quality of life in affected women. Topical ultra-potent corticosteroids continue to be used 
for first-line treatment of vulvar LS with calcineurin inhibitors an acceptable second-line 
therapy, however combination therapy has yet to be studied. Since corticosteroids and 
topical calcineurin inhibitors act on different cellular pathways, the combination of these 
two therapies may be more effective than either individually, and has yet to be studied. 	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METHODS 
Study design 
The study will be a single center randomized double-blind controlled trial on post-
menopausal women with treatment naive vulvar LS evaluating the difference in disease 
symptoms and clinical appearance with monotherapy with ultrapotent corticosteroids 
compared to combination therapy with ultra-potent corticosteroids and calcineurin 
inhibitors. The secondary endpoint will be incidence of relapse.  
 
Study population and sampling 
The sample size was calculated based off of data from previous studies and will be at 
least 32 women total with 16 women in each group50.  
The study population will be all women diagnosed with vulvar LS by 
gynecologists or dermatologists at Boston Medical Center over the span of one year. The 
patients will be selected based on inclusion and exclusion criteria listed in table 1.  
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Table 1. Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
1. Post-menopausal women who are able to 
provide written consent 
2. Subjects have biopsy proven vulvar LS 
3. Subjects’ vulvar LS has been previously 
untreated 
  
1. Any patient with previously treated LS 
2. Any patient who has a history of adverse 
reaction to topical corticosteroids 
3. Any patient who has history of adverse 
reaction to topical calcineurin inhibitors 
4. Any patient who is currently taking 
systemic corticosteroids or calcineurin 
inhibitors 
5. Any patient with additional dermatoses 
in anogenital region 
6. Any patient with co-existing infection in 
anogenital region  
6. History of squamous cell carcinoma or 
malignancy in vulvar region  
7.Any patient who has physical restrictions 
limiting the ability to apply treatments 
8. Any patient who is 
immunocompromised  
  
Treatment (or intervention) Eligible	  patients	  will	  be	  randomized	  to	  the	  control	  group	  or	  experimental group using 
a randomization computer program. The patients will be matched for age and randomized 
1:1. The control group or group A will receive an ultra-potent corticosteroid ointment 
(clobetasol propionate 0.05%) each morning, and a non-medicated vehicle ointment each 
evening. The will be instructed to apply enough ointment to lightly coat the affected area 
with the specific ointment each morning and evening.  
The experimental group or group B will receive combination therapy with an 
ultrapotent corticosteroid ointment (clobetasol propionate 0.05%) in the morning, and 
calcineurin inhibitor ointment (tacrolimus 0.1%) each evening for three months.  
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Study variables and measures 
The primary study outcome will be improvement in symptoms of itching and burning, 
and clinical appearance of disease by evaluating erythema, whitening of the skin, 
hyperkeratosis and purpuric lesions/excoriations.  
To quantify a patient’s itching and burning, VAS-PR and VAS-BP scales, which 
are included in the appendix, will be used which has been used by previous studies and 
evaluates the patients’ itching on a scale from 0-10, and burning on a scale from 0-10 and 
is added together to equal a Global Subjective Scale (GSS)43.  A patient’s GSS will be 
evaluated for improvement in 50% from baseline score.   
To evaluate the patient’s objective appearance of disease, erythema, whitening of 
the skin, and hyperkeratosis, purpuric lesions/excoriations will be evaluated with 0= non-
existent to 3= the most severe for a total of 12 points for a GOS51.  An example of the 
GOS chart is included in appendix. The patients will be evaluated for an improvement in 
GOS in 50% from baseline.  
 In addition to improvement in symptoms and clinical signs of disease, relapse 
incidence will be calculated as a secondary endpoint. Relapse incidence will be 
calculated as the percentage of women who had responded to their designated therapy 
after three months of treatment who develop symptoms or clinical signs of disease 
measured by an increase in GOS and GSS scores by 50% within the year of follow-up 
post treatment which will be evaluated at their one year follow-up appointment.  
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Recruitment 
Patients with newly diagnosed genital LS seen by outpatient dermatology at Boston 
Medical Center over the span of a year will be invited to participate in the study. 
Dermatology providers will be made aware of the study at a faculty meeting and given 
information on how to refer patients for enrollment. Additionally, fliers will be posted 
around Boston Medical Center gynecology staff offices and an e-mail will be sent to 
gynecology physicians, NPs, PAs, and residents to encourage the department of 
gynecology to refer patients to dermatology for the study. A research assistant will 
explain the details of the study to prospective patients.  
 
Data collection 
The patient will fill out a paper survey at the beginning of their visits to evaluate their 
subjective symptoms with the VAS-BP and VAS-PR. After the doctor or PA examines 
the patient’s vulva, they will fill out a paper form evaluating the clinical appearance of 
disease and total the score for the GOS. At the end of each appointment, the research 
assistant will calculate the GSS from the patient’s survey by adding the VAS-PR and 
VAS-BP, and then transfer the data from the paper form to an excel document. 
Paperwork and electronic files for each patient will be labeled with a number unique to 
that patient.  The patient’s identifying information will not be listed on this data to help 
protect privacy.  
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Data analysis 
A statistician will be utilized for analysis of the data. For evaluation of patients’ response 
to treatments, the percent of patients considered responders will be compared between 
groups. The degree of change in score will also be evaluated with the mean change of 
score compared between groups with an unpaired T-test with a p-value of less than 0.05 
considered significant. The GOS and GSS scores will be calculated separately. The risk 
ratio of improvement in 50% in GSS and GOS with combination therapy will be 
calculated.  
 The secondary endpoint of relapse incidence will be calculated in each group 
from patients who were considered responders from treatment. The relative risk of 
relapse will be calculated between groups. Additionally, time to event calculation will 
used for time to relapse and compared between groups using Kaplan Meier curves and 
log rank test. 
 
Timeline and resources 
Patients will be recruited to the study over the span of a year. The patient will need to be 
diagnosed with vulvar LS by the primary investigator (dermatologist or a derm PA) and 
the diagnosis will need to be confirmed with a biopsy of the affected area that is read by a 
pathologist. Once the patient has their diagnosis confirmed, which will take 1-2 weeks, 
and assuming they meet study criteria, they will be randomized to the treatment or 
control groups. A pharmacist will prepare the two ointments for the patient and the 
patient will return to the clinic and be instructed on how to apply the medications. The 
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patient will follow-up with the same provider after three months of treatment, and one 
year post-treatment. The patient will also be instructed to follow-up as needed post-
treatment if signs and symptoms of the disease recur. A medical or PA will be utilized as 
a research assistant during the duration of the study to import data into the computer. A 
secretary will be needed to coordinate follow-up appointments.  Once all the data has 
been collected and recorded on the computer, a statistician will analyze the data.  
Table 2: Resources needed  
Personal  Equipment  
1.PA/Dermatologist 
2.Pathologist 
3.Pharmacist  
4.PA student/Medical student/research 
assistant  
5.Statistician 
1. Biopsy equipment 
2. Ultra-potent corticosteroid ointment 
3. Vehicle placebo ointment 
4. Tacrolimus ointment 
5. Paper surveys for patient to evaluate 
GSS 
6. Surveys for clinician to evaluate GOS 
7. Computers with statistics software  
 
Institutional Review Board 
The study will be submitted to the institutional review board at Boston University 
Medical Center for a full-board review to using INSPIR II application. The study will 
need to be approved by a full-board review due to unknown adverse reactions that could 
be a result of untested combination therapy.  
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CONCLUSION 
Discussion 
Though the proposed study will utilize symptom and appearance scores (GSS and GOS) 
which have been utilized by many other studies on vulvar LS, these scales have not been 
validated and the values that have been chosen for a patient to be a “responder” have 
been used in other small studies but are arbitrary. A large multi-center study proving that 
GOS scores have high inter-observer reproducibility would help to ensure that the scores 
from the proposed study accurately assesses disease severity.  The GSS score may also 
vary from patient to patient depending on their pain tolerance and subjective experience 
of the disease. Additionally, the proposed study design is not evaluating dyspareunia 
because some patients may not be sexually active, and scarring since this is not reversible 
with treatment but these are important and common features of LS.  
 The study population and sample size of this study may also limit generalizability. 
All of the study patients will be from Boston Medical Center and may have different 
proportions of comorbid diseases or environmental risk factors than the general 
population that could play a role on the severity of the disease.  
 Though the proposed study has a secondary outcome of disease relapse within a 
year post-treatment, this may not accurately assess long-term relapse rates in each 
treatment groups. If this study finds that combination therapy is more effective, an 
additional study with longer-term follow-up could help more accurately determine the 
secondary endpoint.  
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Summary 
LS is a debilitating disease causing patients significant pain and discomfort and is 
increasing in prevalence. LS is associated with autoimmune conditions most commonly 
thyroid disorders. Further studies are necessary to understand the pathogenesis of LS but 
theories include exposure to virus, vector-borne bacteria, trauma, urine and urine 
exposure. Vulvar LS can be diagnosed based on clinical appearance and symptoms. 
Diagnosis can be confirmed with a biopsy. Many women with LS suffer for many years 
with itching, burning, dyspareunia, and the fear that LS predisposes them to vulvar SCC.  
There a wide variety of treatment options available to women with vulvar LS with 
topical corticosteroids prescribed as first-line therapy, and topical calcineurin inhibitors 
an appropriate second line therapy. Though there is concern about thinning of the skin 
and increased possibility of infection with topical corticosteroids, current studies have 
found the treatment to be safe and effective in most patients. Topical calcineruin 
inhibitors have a different mechanism of action than topical coritcosteroids and are found 
to be safe with some mild burning and darkening of the skin noted as side effects. The 
studies included in the literature review have small sample sizes, and do not have long-
term follow up.  Topical corticosteorids have been proven to be more effective than 
topical calcinuerin inhibitors but combination therapy may target the disease from 
different molecular pathways and may increase the percentage of women responsive to 
treatment, and may reduce relapse.  
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Clinical and/or public health significance 
Many patients with vulvar LS are refractory to treatment or relapse frequently and suffer 
from the condition for years. If the proposed study finds that combination therapy is more 
effective in treating and helping achieve longer-lasting remission, clinicians will be able 
to treat women more quickly and with greater success than with the current first-line 
treatment. By treating the vulvar LS more effectively, the patient’s quality of life will 
improve and their risk of developing squamous cell carcinoma will decrease. 
While treating the patient and improving their quality of life is the goal of this 
proposal, another benefit would be reducing amount of times patients would need to be 
seen by a dermatologist. The incidence of LS has been found to be increasing and with 
time may represent a greater percentage of dermatology visits, especially if the patients 
do not respond to treatment. In many parts of the country there is a long wait to see a 
dermatologist. In a survey of dermatologists in 2008, with 1243 responding, mean wait 
time for a new patient visit was 33 days52. Though an increase in mid-level providers 
such as PAs may alleviate some of the strain on dermatologists, improved treatments 
such as combination therapy for vulvar LS would be time and cost-effective.   
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APPENDIX 
 
Visual Analogue Scale-PR (Pruritus) 
0 1 2 3 4 5 6 7 8 9 10 
0= absence of symptoms 
5= moderate 
10= worst possible symptoms  
 
Visual Analogue Scale-BP (burning) 
0 1 2 3 4 5 6 7 8 9 10 
0= absence of symptoms 
5= moderate 
10= worst possible symptoms  
 
 
Global Subjective Scale43 = VAS pruritus + Vas burning = 20 (highest possible score) 
 
 
 
Global Objective Scale (GOS)	  51 
 Erythema Leukoderma Hyperkeratosis Purpuric 
Lesions/Excoriations 
Absence (0)     
Mild (1)     
Moderate (2)     
Severe (3)     
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